The 25th of March
Onco Immune Innovative macromolecular drug research and development center
Unveiled in Jiangning High-tech Zone
Not only mark
Nanjing Aoke immune biological medicine Co., LTD. Development
Into the fast lane
It also marks the development of macromolecular innovative drug industry
In Jiangning has entered a new stage
Hu Gang, Vice Chairman of the Standing Committee of the CPPCC of Jiangsu Province, Liu Ling, Chairman of the CPPCC District, Wang Caiquan, deputy district governor and Secretary of the Party Working Committee of Jiangning High-tech Zone, responsible comrades of the Municipal Science and Technology Bureau and the Municipal Investment Promotion Bureau, Liu Yang, founder and chairman of Aoke Immunization, and Zheng Pan, founder of Aoke Immunization, participated in the activity.
In March 2022, Guangzhou Aoke Immune Biotechnology Co., Ltd. signed an agreement with Jiangning High-tech Zone to set up a wholly-owned subsidiary, Nanjing Aoke Immune Biomedicine Co., Ltd. in Jiangning High-tech Zone to build a research and development and industrialization base project. The project will use the 6000 square meters plant in Ruihong Cell and Gene Industrial Park to build a research and development center and pilot workshop to speed up the development and approval process of innovative drug products.
At present, the leased R & D site has completed the R & D laboratory, pilot workshop, quality control laboratory and overall decoration, and will be officially put into use.
With the support of Nanjing Municipal government, Jiangning High-tech Zone, and Jiangning District Investment Promotion Bureau, Angke Immune Innovative macromolecular Drug Research and Development Center successfully landed in Jiangning High-tech Zone and was unveiled on the same day. With a cumulative investment of about 280 million yuan, the center has a number of existing products in research, committed to the development of innovative immunotherapy drugs, and strives to bring more best-in-class/optimal products to clinical patients.
On the same day, the Onco Immune Antibody Coupling Drug Innovation Center was also inaugurated.Antibody coupling drug is a new type of cancer treatment drug, which belongs to the perfect combination of chemotherapy and immunotherapy, and has become a hot track in the layout of global pharmaceutical companies. At the event, Onco Immunology also released three major innovative drug advances in antibody and cell therapy.
Two new drug research and development innovation centers were unveiled, adding new momentum to the development of the biomedical industry in Jiangning High-tech Zone. At present, Jiangning High-tech Zone has gathered more than 300 biomedical enterprises, forming five industrial sectors of pharmaceutical research and development and production, cell therapy, research and development service outsourcing (CRO), testing and inspection, and high-end medical devices, forming a full life cycle innovation ecology covering registration and testing, product certification, technical improvement, and quality system. In the ranking of the development competitiveness of China's biomedical Parks in 2022 released by the China Biotechnology Development Center, the comprehensive competitiveness of Jiangning High-tech Zone ranks 16th in the country and 4th in Jiangsu Province among 220 participating parks, maintaining the rank for four consecutive years.
Next
Jiangning High-tech Zone will open up a green channel for the development of Aoke Immune, set up a special service class and arrange service specialists to assist enterprises, take the initiative to coordinate and solve difficult problems in the progress of the project, fully support enterprise scientific and technological research and development and achievement transformation, help Aoke Immune to build a global innovative drug brand, and accelerate the cultivation of new quality pharmaceutical productivity. Jointly make the biomedicine industry bigger and stronger and make it internationally well-known.
